AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27577513 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral CT imaging (1 ml/kg contrast agent)
Number of subjects: 60
Study 27577513 — intervention group
Group type: COMPARATOR
Intervention: Conventional CT imaging (120 kVp, 1 ml/kg contrast agent)
Number of subjects: 60
Study 24555418 — intervention group
Group type: EXPERIMENTAL
Intervention: Unloading shoes
Number of subjects: 164
Study 24555418 — intervention group
Group type: COMPARATOR
Intervention: Control shoes
Number of subjects: 164
Study 21538098 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 121
Study 21538098 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE)
Number of subjects: 121
Study 21538098 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care (UC)
Number of subjects: 121
Study 21538098 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (non-ADT group)
Number of subjects: 121
Study 21147645 — intervention group
Group type: EXPERIMENTAL
Intervention: He‐O₂ breathing
Number of subjects: 10
Study 21147645 — intervention group
Group type: EXPERIMENTAL
Intervention: SF₆‐O₂ breathing
Number of subjects: 10
Study 21147645 — intervention group
Group type: COMPARATOR
Intervention: Ar‐O₂ breathing
Number of subjects: 10
Study 17230596 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg orally
Number of subjects: 11
Study 17230596 — intervention group
Group type: COMPARATOR
Intervention: Fingolimod 1 mg intravenously infused over 2 h
Number of subjects: 11
Study 14705236 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol (1 micro g/day) alone (alfacalcidol group, n = 11)
Number of subjects: 21
Study 14705236 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol (1 micro g/day) and intermittent cyclical etidronate (200 mg/day for 14 days, given for 4 cycles) (combined group, n = 10)
Number of subjects: 21
Study 12203742 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week psychoeducational intervention
Number of subjects: 89
Study 12203742 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 89
Study 9523407 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality Salience (MS)
Number of subjects: 4
Study 9523407 — intervention group
Group type: COMPARATOR
Intervention: Control topic
Number of subjects: 4
Study 7665805 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright-light therapy
Number of subjects: 30
Study 7665805 — intervention group
Group type: EXPERIMENTAL
Intervention: Dim light (after bright-light therapy)
Number of subjects: 30
Study 7665805 — intervention group
Group type: COMPARATOR
Intervention: Bright-light therapy (control group)
Number of subjects: 30
Study 7665805 — intervention group
Group type: COMPARATOR
Intervention: Dim light (control group)
Number of subjects: 30
Study 2744907 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinaverium bromide (10 subjects)
Number of subjects: 20
Study 2744907 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 subjects)
Number of subjects: 20
Study 58258 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 29
Study 58258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 30818311 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sialagogue spray containing malic acid 1% (SalivAktive®)
Number of subjects: 28
Study 30818311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 28493922 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable system (Inion CPS)
Number of subjects: 221
Study 28493922 — intervention group
Group type: COMPARATOR
Intervention: Titanium system (KLS Martin)
Number of subjects: 221
Study 28493922 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Biodegradable and Titanium)
Number of subjects: 221
Study 25613996 — intervention group
Group type: EXPERIMENTAL
Intervention: Berlin Heart EXCOR(®) device
Number of subjects: 204
Study 23334820 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-unit, interactive, standardized programme based on the comprehensive social influence model
Number of subjects: 173
Study 22164629 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribendimdine
Number of subjects: 47
Study 22164629 — intervention group
Group type: COMPARATOR
Intervention: Albendazole
Number of subjects: 47
Study 19631559 — intervention group
Group type: COMPARATOR
Intervention: JVIR articles
Number of subjects: 215
Study 19631559 — intervention group
Group type: COMPARATOR
Intervention: CVIR articles
Number of subjects: 215
Study 19631559 — intervention group
Group type: COMPARATOR
Intervention: Randomized studies in JVIR
Number of subjects: 215
Study 19631559 — intervention group
Group type: COMPARATOR
Intervention: Randomized studies in CVIR
Number of subjects: 215
Study 17082278 — intervention group
Group type: EXPERIMENTAL
Intervention: High-viscosity glass ionomer cement (GIC)
Number of subjects: 219
Study 17082278 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-based composite
Number of subjects: 219
Study 17082278 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Class II restorations
Number of subjects: 219
Study 17082278 — intervention group
Group type: EXPERIMENTAL
Intervention: Both materials
Number of subjects: 219
Study 12832297 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic index diet
Number of subjects: 36
Study 12832297 — intervention group
Group type: COMPARATOR
Intervention: High-glycemic index diet
Number of subjects: 36
Study 11016777 — intervention group
Group type: EXPERIMENTAL
Intervention: iobitridol 300 (low‐osmolar, 300 mg I/ml)
Number of subjects: 212
Study 11016777 — intervention group
Group type: EXPERIMENTAL
Intervention: iobitridol 350 (low‐osmolar, 350 mg I/ml)
Number of subjects: 212
Study 11016777 — intervention group
Group type: COMPARATOR
Intervention: ioxithalamate 350 (high‐osmolar, 350 mg I/ml)
Number of subjects: 212
Study 8843536 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 16
Study 8843536 — intervention group
Group type: COMPARATOR
Intervention: Clonazepam
Number of subjects: 16
Study 1617576 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing music therapy
Number of subjects: 40
Study 1617576 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music therapy)
Number of subjects: 40
Study 6703818 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous verapamil hydrochloride (0.075 mg/kg and 0.15 mg/kg given 15 minutes apart)
Number of subjects: 14
Study 6703818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 6703818 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous verapamil hydrochloride
Number of subjects: 14
Study 30221330 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and intra-articular TXA and RIV postoperatively (Group A)
Number of subjects: 158
Study 30221330 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and intra-articular TXA and LMWH postoperatively (Group B)
Number of subjects: 158
Study 30221330 — intervention group
Group type: COMPARATOR
Intervention: Saline and RIV postoperatively (Group C)
Number of subjects: 158
Study 31584145 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide-formoterol (ICS-LABA) as rescue medication
Number of subjects: 0
Study 31584145 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide-formoterol (ICS-LABA) on demand
Number of subjects: 0
Study 31584145 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide-formoterol (ICS-LABA) used as needed
Number of subjects: 0
Study 31584145 — intervention group
Group type: COMPARATOR
Intervention: ICS-LABA combination used as needed
Number of subjects: 0
Study 31584145 — intervention group
Group type: COMPARATOR
Intervention: Chronic ICS treatment
Number of subjects: 0
Study 31584145 — intervention group
Group type: COMPARATOR
Intervention: SABA alone
Number of subjects: 0
Study 31584145 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone (ICS) and tiotropium (antimuscarinic)
Number of subjects: 0
Study 28598858 — intervention group
Group type: EXPERIMENTAL
Intervention: Real iTBS
Number of subjects: 10
Study 28598858 — intervention group
Group type: COMPARATOR
Intervention: Sham iTBS
Number of subjects: 10
Study 25740537 — intervention group
Group type: EXPERIMENTAL
Intervention: D2-receptor antagonist amisulpride
Number of subjects: 0
Study 25740537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23748693 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed observation (both expert and novice models)
Number of subjects: 0
Study 23748693 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed observation and expert observation
Number of subjects: 0
Study 23748693 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical practice trials interspersed with observation
Number of subjects: 0
Study 21489663 — intervention group
Group type: EXPERIMENTAL
Intervention: diet + PS (2 g/day)
Number of subjects: 24
Study 21489663 — intervention group
Group type: COMPARATOR
Intervention: healthy diet
Number of subjects: 24
Study 21489663 — intervention group
Group type: EXPERIMENTAL
Intervention: healthy diet + PS
Number of subjects: 24
Study 21489663 — intervention group
Group type: EXPERIMENTAL
Intervention: PS supplementation
Number of subjects: 24
Study 21489663 — intervention group
Group type: COMPARATOR
Intervention: diet
Number of subjects: 24
Study 18577159 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin (insulin glargine) added to existing oral therapy
Number of subjects: 0
Study 18577159 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid-acting insulin (insulin glulisine)
Number of subjects: 0
Study 18577159 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimization of basal insulin dose with addition of prandial insulin
Number of subjects: 0
Study 18577159 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal-bolus insulin strategy
Number of subjects: 0
Study 18577159 — intervention group
Group type: EXPERIMENTAL
Intervention: Premixed insulin strategy
Number of subjects: 0
Study 17137975 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonventing curette with pump settings of 5 mL/min and 10 mm Hg
Number of subjects: 0
Study 17137975 — intervention group
Group type: EXPERIMENTAL
Intervention: Venting curette with pump settings of 7 to 10 mL/min and 50 mm Hg
Number of subjects: 0
Study 17137975 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass hole in the curette
Number of subjects: 0
Study 12617523 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified wavelet de‐noising procedure
Number of subjects: 12
Study 11406327 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensatory visual field training for 4 weeks
Number of subjects: 21
Study 11406327 — intervention group
Group type: COMPARATOR
Intervention: Control group (23 healthy individuals)
Number of subjects: 21
Study 9256222 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab bolus plus infusion
Number of subjects: 2099
Study 9256222 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab bolus only
Number of subjects: 2099
Study 9256222 — intervention group
Group type: COMPARATOR
Intervention: Placebo only
Number of subjects: 2099
Study 8273616 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-osmolality radiologic contrast media
Number of subjects: 1004
Study 8273616 — intervention group
Group type: COMPARATOR
Intervention: High-osmolality radiologic contrast media
Number of subjects: 1004
Study 8273616 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac angiography
Number of subjects: 1004
Study 8273616 — intervention group
Group type: EXPERIMENTAL
Intervention: Body CT
Number of subjects: 1004
Study 8273616 — intervention group
Group type: EXPERIMENTAL
Intervention: History of unstable angina
Number of subjects: 1004
Study 8273616 — intervention group
Group type: EXPERIMENTAL
Intervention: No history of unstable angina
Number of subjects: 1004
Study 8273616 — intervention group
Group type: EXPERIMENTAL
Intervention: History of renal insufficiency
Number of subjects: 1004
Study 8273616 — intervention group
Group type: EXPERIMENTAL
Intervention: No history of renal insufficiency
Number of subjects: 1004
Study 8273616 — intervention group
Group type: EXPERIMENTAL
Intervention: Two adverse reactions
Number of subjects: 1004
Study 8273616 — intervention group
Group type: EXPERIMENTAL
Intervention: Three or more adverse reactions
Number of subjects: 1004
Study 8273616 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboembolic reaction
Number of subjects: 1004
Study 3305620 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-fluoride gel
Number of subjects: 34
Study 3305620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 3305620 — intervention group
Group type: COMPARATOR
Intervention: Fluoride gel
Number of subjects: 34
Study 30962409 — intervention group
Group type: EXPERIMENTAL
Intervention: HL301 (600 mg/day)
Number of subjects: 166
Study 30962409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 30303956 — intervention group
Group type: EXPERIMENTAL
Intervention: Women empowerment intervention
Number of subjects: 1463
Study 30303956 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma exposure
Number of subjects: 1463
Study 30303956 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 1463
Study 30303956 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood trauma exposure
Number of subjects: 1463
Study 30303956 — intervention group
Group type: EXPERIMENTAL
Intervention: Community gender attitudes
Number of subjects: 1463
Study 28090203 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal extracts (experimental group)
Number of subjects: 32
Study 28090203 — intervention group
Group type: COMPARATOR
Intervention: Control group (glasses without herbal extracts)
Number of subjects: 32
Study 23911560 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical staging via a minimally invasive extraperitoneal approach followed by tailored radiotherapy with chemotherapy
Number of subjects: 600
Study 23911560 — intervention group
Group type: COMPARATOR
Intervention: Pelvic radiotherapy with chemotherapy (standard-of-care arm)
Number of subjects: 600
Study 23093136 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (n=265) aiming at weight reduction, dietary modification, and increased physical activity.
Number of subjects: 522
Study 23093136 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=257) receiving general lifestyle information.
Number of subjects: 522
Study 23093136 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (n=265)
Number of subjects: 522
Study 23093136 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=257)
Number of subjects: 522
Study 21481394 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg + Simvastatin 20mg (EZE+S)
Number of subjects: 15
Study 21481394 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Simvastatin 20mg (P+S)
Number of subjects: 15
Study 18086800 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant oophorectomy and tamoxifen for 5 years
Number of subjects: 709
Study 16513003 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (200 mg)
Number of subjects: 64
Study 16513003 — intervention group
Group type: COMPARATOR
Intervention: Inert placebo
Number of subjects: 64
Study 16513003 — intervention group
Group type: EXPERIMENTAL
Intervention: Aging
Number of subjects: 64
Study 12695318 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychoeducation (21 sessions)
Number of subjects: 120
Study 12695318 — intervention group
Group type: COMPARATOR
Intervention: Nonstructured group meetings (21 sessions)
Number of subjects: 120
Study 11123451 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole troche (10 mg, five times daily)
Number of subjects: 29
Study 11123451 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole oral solution (100 mg/10 mL, twice daily)
Number of subjects: 29
Study 11123451 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole troche
Number of subjects: 29
Study 11123451 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole oral solution
Number of subjects: 29
Study 9368814 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron fortification present
Number of subjects: 15
Study 9368814 — intervention group
Group type: COMPARATOR
Intervention: Iron fortification withdrawn
Number of subjects: 15
Study 8469556 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (0.025%)
Number of subjects: 30
Study 8469556 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate (0.12%)
Number of subjects: 30
Study 8469556 — intervention group
Group type: COMPARATOR
Intervention: Iso‐Dent (control)
Number of subjects: 30
Study 3328853 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine (100 mg capsules and 150 mg suppositories)
Number of subjects: 586
Study 3328853 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine
Number of subjects: 586
Study 3328853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 586
Study 29793857 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab (300 mg) administered subcutaneously every 2 weeks
Number of subjects: 79
Study 29793857 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered subcutaneously every 2 weeks
Number of subjects: 79
Study 25812080 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment-focused integrative reminiscence (AFIR) intervention
Number of subjects: 0
Study 24966303 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple sclerosis group
Number of subjects: 18
Study 24966303 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 23025333 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured graft consisting of autologous cultured melanocytes on poly (DL‐lactic acid) film
Number of subjects: 22
Study 23025333 — intervention group
Group type: COMPARATOR
Intervention: Polyurethane dressing (control arm)
Number of subjects: 22
Study 16317125 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole flaxseed
Number of subjects: 12
Study 16317125 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed flaxseed
Number of subjects: 12
Study 16317125 — intervention group
Group type: COMPARATOR
Intervention: Ground flaxseed
Number of subjects: 12
Study 12181509 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aid provision
Number of subjects: 133
Study 12181509 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hearing aid provision)
Number of subjects: 133
Study 9695717 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram (500 mg oral)
Number of subjects: 10
Study 9695717 — intervention group
Group type: COMPARATOR
Intervention: Control (no pretreatment)
Number of subjects: 10
Study 7647823 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately energy-restricted diet (ER)
Number of subjects: 24
Study 7647823 — intervention group
Group type: COMPARATOR
Intervention: Control group (weight-maintaining diet)
Number of subjects: 24
Study 2757680 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg nifedipine preparation (test preparation)
Number of subjects: 16
Study 2757680 — intervention group
Group type: COMPARATOR
Intervention: Marketed reference preparation (control)
Number of subjects: 16
Study 2757680 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preparations (test and reference)
Number of subjects: 16
Study 320940 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% clotrimazole solution
Number of subjects: 0
Study 320940 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 31758926 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly 0.3‐mg intravitreal ranibizumab injections
Number of subjects: 24
Study 29721714 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral feeding after distal gastrectomy (DG)
Number of subjects: 0
Study 29721714 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral feeding after total gastrectomy (TG)
Number of subjects: 0
Study 29721714 — intervention group
Group type: COMPARATOR
Intervention: Conventional postoperative management after distal gastrectomy (DG)
Number of subjects: 0
Study 29721714 — intervention group
Group type: COMPARATOR
Intervention: Conventional postoperative management after total gastrectomy (TG)
Number of subjects: 0
Study 26768692 — intervention group
Group type: EXPERIMENTAL
Intervention: CF-on (CF >10 grams; n = 25)
Number of subjects: 50
Study 26768692 — intervention group
Group type: COMPARATOR
Intervention: CF-off (CF blinded; n = 25)
Number of subjects: 50
Study 26768692 — intervention group
Group type: COMPARATOR
Intervention: CF-off
Number of subjects: 50
Study 26768692 — intervention group
Group type: EXPERIMENTAL
Intervention: CF-on
Number of subjects: 50
Study 24397625 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase clostridium histolyticum (CCH)
Number of subjects: 58
Study 22658249 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5mg/kg
Number of subjects: 40
Study 22658249 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 1mg/kg
Number of subjects: 40
Study 22658249 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 1 μg/kg plus Ropivacaine 0.5mg/kg
Number of subjects: 40
Study 22658249 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 1 μg/kg, Ropivacaine 0.5mg/kg plus Epinephrine 6 μg/kg
Number of subjects: 40
Study 20421121 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 150 mg daily
Number of subjects: 118
Study 20421121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 18697911 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet (HP; 3.0 g protein x kg fat‐free mass (FFM)(‐1) x day(‐1))
Number of subjects: 19
Study 18697911 — intervention group
Group type: COMPARATOR
Intervention: Usual protein intake (UP; 1.5 g protein x kg FFM(‐1) x day(‐1))
Number of subjects: 19
Study 18697911 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet (HP)
Number of subjects: 19
Study 15716250 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation
Number of subjects: 25
Study 15716250 — intervention group
Group type: COMPARATOR
Intervention: Nonaccelerated rehabilitation
Number of subjects: 25
Study 12374436 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of emotional state (happiness, sadness)
Number of subjects: 0
Study 12374436 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional states (happiness, sadness)
Number of subjects: 0